Chemfab alkalis Limited has announced that its Board of Directors will convene on January 28, 2026, to review and approve the company's unaudited financial results for the third quarter of fiscal year 2026. The meeting, scheduled for 2:00 PM, will focus on the financial performance for the quarter and nine months ended December 31, 2025.

Board Meeting Details

The company has formally notified both the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) about the upcoming board meeting in compliance with regulatory requirements. This notification was made pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Trading Window Closure

In accordance with the company's Code of Prevention of Insider Trading and SEBI (Prohibition of Insider Trading) Regulations, 2015, Chemfab Alkalis Limited has implemented a trading window closure for all stakeholders. This restriction affects directors, designated employees, other insiders of the company, and their relatives.

The trading window closure details are as follows:

Regulatory Compliance

The announcement demonstrates the company's adherence to regulatory frameworks governing listed entities in India. The formal communication was signed by Bharatraj Panchal, Company Secretary (FCS: 9828), and digitally authenticated on January 22, 2026.

Chemfab Alkalis Limited operates as part of Dr. Rao's Group of Companies and maintains certifications including OHSAS 18001 and ISO 14001. The company's registered office is located at 'TEAM House', GST Road, Vandalur, Chennai, while its manufacturing plant is situated at 'Gnanananda Place', Kalapet, Puducherry.

Market Information

The company trades on both major Indian stock exchanges with the following identifiers:

• BSE Scrip Code: 541269
• NSE Symbol: CHEMFAB
• CIN: L24290TN2009PLC071563

Investors and stakeholders can expect the Q3FY26 financial results to be announced following the board meeting on January 28, 2026, after which normal trading activities will resume within the specified timeframe.

Chemfab Alkalis Ltd has successfully commissioned a new Ineos electrolyser system, marking the completion of a significant technological upgrade in its manufacturing operations. The company officially announced the commissioning under Regulation 30 of SEBI listing requirements, confirming the replacement of equipment that had been operational for 30 years.

Investment and Equipment Details

The modernization project represents a substantial capital commitment financed entirely through internal resources:

Expected Operational Benefits

The company anticipates multiple operational improvements from this equipment upgrade. The new Ineos electrolyser is expected to deliver enhanced operating rates with better reliability compared to the previous system. Additionally, the modern technology is projected to generate significant power savings, contributing to improved operational efficiency and cost optimization.

Implementation Timeline and Capacity

Chemfab Alkalis expects the benefits from this technological upgrade to become apparent starting from the fourth quarter of fiscal year 2026. The consent capacity remains unchanged at 180 tonnes per day, ensuring continuity in production capabilities while enhancing efficiency parameters.

Strategic Significance

The successful commissioning demonstrates the company's commitment to technological advancement and operational excellence. By financing this major capital expenditure through internal accruals, Chemfab Alkalis showcases its strong financial position and strategic focus on modernizing its chemical manufacturing operations for enhanced competitiveness.